HK1120452A1 - A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle - Google Patents

A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle

Info

Publication number
HK1120452A1
HK1120452A1 HK08113799.8A HK08113799A HK1120452A1 HK 1120452 A1 HK1120452 A1 HK 1120452A1 HK 08113799 A HK08113799 A HK 08113799A HK 1120452 A1 HK1120452 A1 HK 1120452A1
Authority
HK
Hong Kong
Prior art keywords
cell
biomolecule
delivery
organelle
membrane enclosed
Prior art date
Application number
HK08113799.8A
Other languages
English (en)
Inventor
Sarah Fredriksson
Sylvia Koivunen
Fredrik Olsson
Hanna-Karin Toftevall
Original Assignee
Genovis Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genovis Ab filed Critical Genovis Ab
Publication of HK1120452A1 publication Critical patent/HK1120452A1/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK08113799.8A 2005-08-19 2008-12-19 A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle HK1120452A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70945405P 2005-08-19 2005-08-19
PCT/SE2006/000960 WO2007021236A1 (en) 2005-08-19 2006-08-21 A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle

Publications (1)

Publication Number Publication Date
HK1120452A1 true HK1120452A1 (en) 2009-04-03

Family

ID=37757824

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113799.8A HK1120452A1 (en) 2005-08-19 2008-12-19 A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle

Country Status (10)

Country Link
US (1) US8557289B2 (xx)
EP (1) EP1940513A4 (xx)
JP (1) JP4965570B2 (xx)
KR (1) KR101331891B1 (xx)
CN (1) CN101242870B (xx)
AU (1) AU2006280519B2 (xx)
CA (1) CA2619118A1 (xx)
HK (1) HK1120452A1 (xx)
IL (1) IL189559A (xx)
WO (1) WO2007021236A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671806A1 (en) * 2006-12-08 2008-06-19 Austin M. Derfus Remotely triggered release from heatable surfaces
US20110008304A1 (en) * 2007-07-09 2011-01-13 Kansas State University Research Foundation Use of cells to facilitate targeted delivery of nanoparticle therapies
US20090280063A1 (en) * 2008-05-09 2009-11-12 General Electric Company Novel pei-peg graft copolymer coating of iron oxide nanoparticles for inflammation imaging
EP2575896A2 (en) * 2010-05-26 2013-04-10 Erik Reimhult Magnetically responsive membrane structures
CN101974152B (zh) * 2010-09-28 2012-07-11 山东大学 一种类脂-阳离子聚合物及其制备方法
US9849193B2 (en) * 2013-02-08 2017-12-26 University Of Louisville Research Foundation, Inc. Nanoparticles for drug delivery
EP3162361A1 (en) 2015-11-02 2017-05-03 Universität für Bodenkultur Wien Improved magnetically reactive vesicular bodies
WO2019157319A1 (en) * 2018-02-12 2019-08-15 Flagship Pioneering Innovations V, Inc. Devices and methods for delivering material into a biological tissue or cell
US20220107246A1 (en) * 2019-02-01 2022-04-07 University Of Washington Noncovalent tags and related methods for cytosolic delivery of macrobiomolecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928958A (en) 1994-07-27 1999-07-27 Pilgrimm; Herbert Superparamagnetic particles, process for their manufacture and usage
DE60009547T2 (de) 1999-09-08 2004-09-23 Genovis Ab Verfahren zur Poration biologischer Membranen
US20030211045A1 (en) 2001-02-05 2003-11-13 Danuta Leszcyznska Magnetoliposome composition for targeted treatment of biological tissue and associated methods
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
SE522099C2 (sv) * 2002-06-07 2004-01-13 Genovis Ab Anordning för multipel simultan genöverföring
SE0202725D0 (sv) * 2002-09-12 2002-09-12 Genovis Ab Anordning för magnetiskt inducerbar membrantransport
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
CN1537646A (zh) * 2003-10-22 2004-10-20 高春平 肿瘤局部综合治疗方法和装置
US20070196281A1 (en) 2003-12-31 2007-08-23 Sungho Jin Method and articles for remote magnetically induced treatment of cancer and other diseases, and method for operating such article
EP1718341A2 (en) 2004-01-20 2006-11-08 Alnis Biosciences, Inc. Articles comprising magnetic material and bioactive agents

Also Published As

Publication number Publication date
US8557289B2 (en) 2013-10-15
CN101242870B (zh) 2013-01-09
US20090304796A1 (en) 2009-12-10
KR20080053305A (ko) 2008-06-12
AU2006280519B2 (en) 2011-06-16
JP2009504181A (ja) 2009-02-05
JP4965570B2 (ja) 2012-07-04
IL189559A0 (en) 2008-08-07
EP1940513A4 (en) 2013-03-13
AU2006280519A1 (en) 2007-02-22
EP1940513A1 (en) 2008-07-09
KR101331891B1 (ko) 2013-11-21
CA2619118A1 (en) 2007-02-22
IL189559A (en) 2011-07-31
CN101242870A (zh) 2008-08-13
WO2007021236A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
HK1120452A1 (en) A nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle
GB2426343B (en) Open electrochemical sensor
EP1901379A4 (en) Disconnect membrane for a fuel cell
ZA200805735B (en) Hydrogen-generating fuel cell cartridges
EP1882736A4 (en) RECIPIENT CELL CULTURE
GB2436695B (en) Electrochemical gas sensor
ZA200802864B (en) Fuel cartridge for fuel cells
IL193721A0 (en) Polypeptide producing cells
ZA200901162B (en) Programmable buoyant delivery technology
EP2005161A4 (en) ELECTROCHEMICAL SENSOR
EP2044192A4 (en) PLATFORMS FOR IMPROVED OXYGEN CELL CULTURES
ZA200808296B (en) Gas-diffusion electrode for electrolyte-percolating cell
GB0700556D0 (en) Electrochemical gas sensor
GB0611736D0 (en) Ion-conducting membrane
GB0908679D0 (en) Electrochemical gas sensor
EP2028264A4 (en) CELL INCUBATOR
EP2219024A4 (en) ELECTROCHEMICAL OXYGEN SENSOR
EP1999814A4 (en) INTEGRATED FUEL MICRO-CELL DEVICE
EP1873853A4 (en) FUEL CELL
ZA200809370B (en) Lithium ion-selective membrane
EP1863112A4 (en) FUEL CELL
PL1746336T3 (pl) Membrana do zbiornika gazowego
EP1860135A4 (en) ELECTROLYTE MEMBRANE
EP2109172A4 (en) ELECTROLYTE MEMBRANE
PL2062965T3 (pl) Pokrywa zbiornika z membraną gazową

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160821